Abbott to pay almost $385 million to settle false claims allegation about infant formula
Abbott Laboratories will pay $384.999 million to settle DOJ allegations of false claims related to its 2022 infant formula crisis. The settlement resolves claims about non-compliance with safety requirements at its Sturgis, MI, and Casa Grande, AZ, facilities. The company's recall led to a nationwide formula shortage. The settlement does not determine liability. Abbott's payment includes $348.7 million to the U.S. and $36.3 million to states. The DOJ alleged Abbott knowingly manufactured contami
How this was made
The 30-second read
Why it matters
The $385 million settlement resolves government claims but underscores compliance failures at Abbott's Sturgis and Casa Grande plants.
Market read
The settlement introduces a material legal expense and reputational risk for Abbott, likely prompting short‑term stock pressure and heightened sector scrutiny.
What to watch
Potential for future regulatory scrutiny or additional claims could arise, extending risk beyond the disclosed amount.
Background
Abbott faced a federal investigation after a 2022 infant formula crisis that caused infant deaths and a nationwide shortage.
Ticker impact
Abbott Laboratories agreed to pay $385 million to settle False Claims Act allegations related to its infant formula production.
Potential short‑term downside of 2‑4% as investors price in the settlement expense.
Large, disclosed settlement amount is material and newly reported, likely to trigger immediate market reaction.
Market effects
Highlights regulatory risk in the consumer health and nutrition sector, potentially affecting peers like Mead Johnson and Reckitt.
May weigh on US healthcare stocks and could influence sentiment toward companies with government contracts.
Sets a precedent for enforcement actions on infant formula manufacturers worldwide.
Counterpoint
The settlement is a one‑off charge; long‑term fundamentals of Abbott's diversified portfolio remain strong.
Key entities
- companyAbbott Laboratories
US‑listed healthcare company settling False Claims Act allegations.
- government_agencyU.S. Department of Justice
Agency that negotiated the settlement with Abbott.
